| pubmed-article:8428104 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8428104 | lifeskim:mentions | umls-concept:C0023903 | lld:lifeskim |
| pubmed-article:8428104 | lifeskim:mentions | umls-concept:C0060933 | lld:lifeskim |
| pubmed-article:8428104 | lifeskim:mentions | umls-concept:C0060934 | lld:lifeskim |
| pubmed-article:8428104 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:8428104 | lifeskim:mentions | umls-concept:C2711860 | lld:lifeskim |
| pubmed-article:8428104 | lifeskim:mentions | umls-concept:C0166237 | lld:lifeskim |
| pubmed-article:8428104 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8428104 | pubmed:dateCreated | 1993-3-9 | lld:pubmed |
| pubmed-article:8428104 | pubmed:abstractText | A new hepatobiliary contrast agent for magnetic resonance (MR) imaging, gadolinium-ethoxybenzyl (EOB)-diethylemetriaminepentaacetic acid (DTPA), was compared with Gd-DTPA to define the potential for improving tumor-liver contrast in a rodent liver adenocarcinoma model. With a T1-weighted spin-echo sequence, the contrast-to-noise ratio (C/N) for tumor before contrast agent administration was 5 (arbitrary units), the tumor appearing slightly hypo-intense with respect to liver parenchyma. After Gd-DTPA injection (0.1 mmol/kg), tumor enhanced more strongly than liver, resulting in an equalization of tumor and liver signal intensities and a decline in C/N to zero at 3 minutes after injection. After Gd-EOB-DTPA injection (0.1 mmol/kg), liver enhanced more strongly than tumor. Five minutes after injection, C/N increased from 5 to 25 and remained above 17 for 50 minutes. The data indicate that Gd-EOB-DTPA yields higher and more prolonged tumor-liver contrast than Gd-DTPA on T1-weighted spin-echo images. The high liver-tumor contrast after Gd-EOB-DTPA administration should prove clinically advantageous for MR imaging detection of focal hepatic masses. | lld:pubmed |
| pubmed-article:8428104 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8428104 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8428104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8428104 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8428104 | pubmed:issn | 1053-1807 | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:BraschR CRC | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:RosenauWW | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:MühlerAA | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:BerthezèneYY | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:KuwatsuruRR | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:VexlerV SVS | lld:pubmed |
| pubmed-article:8428104 | pubmed:author | pubmed-author:CleméntOO | lld:pubmed |
| pubmed-article:8428104 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8428104 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:8428104 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8428104 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8428104 | pubmed:pagination | 71-7 | lld:pubmed |
| pubmed-article:8428104 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:meshHeading | pubmed-meshheading:8428104-... | lld:pubmed |
| pubmed-article:8428104 | pubmed:articleTitle | Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors. | lld:pubmed |
| pubmed-article:8428104 | pubmed:affiliation | Department of Radiology, University of California, San Francisco 94143-0628. | lld:pubmed |
| pubmed-article:8428104 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8428104 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8428104 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8428104 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
